DEVELOPMENT, PHYSICOCHEMICAL CHARACTERIZATION AND PRECLINICAL EFFICACY EVALUATION OF A WATER-SOLUBLE GLUCAN SULFATE DERIVED FROM SACCHAROMYCES-CEREVISIAE

被引:62
作者
WILLIAMS, DL
PRETUS, HA
MCNAMEE, RB
JONES, EL
ENSLEY, HE
BROWDER, IW
DILUZIO, NR
机构
[1] TULANE UNIV,SCH MED,DEPT SURG,GLUCAN RES LAB,NEW ORLEANS,LA 70112
[2] TULANE UNIV,DEPT CHEM,NEW ORLEANS,LA 70118
来源
IMMUNOPHARMACOLOGY | 1991年 / 22卷 / 03期
关键词
BETA-1,3-D-GLUCAN; GLUCAN SULFATE; IMMUNOMODULATOR; BIOLOGICAL RESPONSE MODIFIER; PRECLINICAL EFFICACY EVALUATION;
D O I
10.1016/0162-3109(91)90039-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This report describes the development, characterization and preclinical efficacy evaluation of water soluble glucan sulfate. Glucan sulfate was derived from insoluble beta-1,3-D-glucan isolated from Saccharomyces cerevisiae. The proposed repeating unit empirical formula of glucan sulfate is [(C6H10O5)5.3H2SO4]n. Two polymer peaks were resolved by aqueous high-performance size exclusion chromatography (HPSEC) with on-line multi-angle laser light scattering (MALLS) photometry and differential viscometry. Peak 1 (M(w) = 1 219 697 Da) represents almost-equal-to 1% of the total polymers, while peak 2 (M(w) = 8 884 Da) accounts for almost-equal-to 99% of polymers. C-13-NMR spectroscopy suggests that glucan sulfate polymer strands may be partially cross-linked. Glucan sulfate (250 mg/kg, i.v.) increased (P < 0.01) macrophage vascular clearance of I-131-reticuloendothelial emulsion by 42% (P < 0.01) and in vitro bone marrow proliferation by 46% (P < 0.05). Glucan sulfate (250 mg/kg, i.v.) increased (P < 0.05) median survival time of C57B1/6J mice with syngeneic melanoma B16 or sarcoma M5076. In addition, glucan sulfate immunoprophylaxis increased resistance of mice to challenge with Escherichia coli, Candida albicans or Mouse Hepatitis Virus strain A-59. We concluded that: (1) insoluble beta-1,3-D-glucan can be converted to a water soluble sulfated form; (2) glucan sulfate activates macrophages and stimulates bone marrow; (3) glucan sulfate exerts antitumor therapeutic activity, and (4) glucan sulfate immunoprophylaxis will modify the course of experimental infectious disease.
引用
收藏
页码:139 / 155
页数:17
相关论文
共 70 条
[1]  
ANDO T, 1984, JPN J CANC CHEMOTHER, V11, P827
[2]   MECHANISM OF INHIBITORY EFFECT OF DEXTRAN SULFATE AND HEPARIN ON REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS INVITRO [J].
BABA, M ;
PAUWELS, R ;
BALZARINI, J ;
ARNOUT, J ;
DESMYTER, J ;
DECLERCQ, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) :6132-6136
[3]   A COMPARATIVE-EVALUATION OF PARTICULATE AND SOLUBLE GLUCAN IN AN ENDOTOXIN MODEL [J].
BOWERS, GJ ;
PATCHEN, ML ;
MACVITTIE, TJ ;
HIRSCH, EF ;
FINK, MP .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1986, 8 (03) :313-321
[4]   MODIFICATION OF POSTOPERATIVE C-ALBICANS SEPSIS BY GLUCAN IMMUNOSTIMULATION [J].
BROWDER, IW ;
WILLIAMS, DL ;
KITAHAMA, A ;
DILUZIO, NR .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1984, 6 (01) :19-26
[5]  
BROWDER IW, 1977, SURG FORUM, V28, P172
[6]  
BROWDER W, 1987, SURGERY, V102, P206
[7]  
BROWDER W, 1988, SURGERY, V104, P224
[8]   PROTECTIVE EFFECT OF NONSPECIFIC IMMUNOSTIMULATION IN POSTSPLENECTOMY SEPSIS [J].
BROWDER, W ;
RAKINIC, J ;
MCNAMEE, R ;
JONES, E ;
WILLIAMS, D ;
DILUZIO, N .
JOURNAL OF SURGICAL RESEARCH, 1983, 35 (06) :474-479
[9]  
BROWDER W, 1990, ANN SURG, V211, P605
[10]  
BROWDER W, 1983, SURV IMMUNOL RES, V2, P299